PURPOSE: Thermotherapy using magnetic nanoparticles (nano cancer therapy) is a new concept of local tumour therapy, which is based on controlled heating of intra-tumoural injected magnetic nanoparticles. The aim of this study was to evaluate the usefulness of PET with a recently introduced amino acid tracer O-(2-[18F]fluoroethyl)-]L-tyrosine (FET) for targeting the nanoparticles implantation. MATERIALS AND METHODS: Eleven patients with glioblastoma recurrences underwent MR and FET-PET imaging for planning of the nano cancer therapy. Thereafter, the gross tumour volumes (GTV) were defined, taking into consideration the results of both imaging tools. RESULTS: The MRI-based mean GTV was 24.3 cm3 (range 2.5-59.7) and the PET-based mean GTV 31.9 cm3 (range 5.2-77.9). On the average the MRI identified an additional 8.9 +/- 4.7 cm3 and the FET-PET scan-an additional 16.5 +/- 15.2 cm3 outside of the common GTV (15.4 +/- 11.0 cm3). The mean final GTV accounted to 33.8 cm3 (range, 5.2-77.9). The additional information of FET-PET led to an increase in GTV by 22-286% in eight patients and to a decrease of 23% and 26%, respectively, in two patients. In one patient, the final GTV was defined on the basis of MRI data only. CONCLUSIONS: FET-PET adds important information on the actual tumour volume in recurrent glioblastomas and is highly valuable for defining the target volume for the nano cancer therapy.
PURPOSE: Thermotherapy using magnetic nanoparticles (nano cancer therapy) is a new concept of local tumour therapy, which is based on controlled heating of intra-tumoural injected magnetic nanoparticles. The aim of this study was to evaluate the usefulness of PET with a recently introduced amino acid tracer O-(2-[18F]fluoroethyl)-]L-tyrosine (FET) for targeting the nanoparticles implantation. MATERIALS AND METHODS: Eleven patients with glioblastoma recurrences underwent MR and FET-PET imaging for planning of the nano cancer therapy. Thereafter, the gross tumour volumes (GTV) were defined, taking into consideration the results of both imaging tools. RESULTS: The MRI-based mean GTV was 24.3 cm3 (range 2.5-59.7) and the PET-based mean GTV 31.9 cm3 (range 5.2-77.9). On the average the MRI identified an additional 8.9 +/- 4.7 cm3 and the FET-PET scan-an additional 16.5 +/- 15.2 cm3 outside of the common GTV (15.4 +/- 11.0 cm3). The mean final GTV accounted to 33.8 cm3 (range, 5.2-77.9). The additional information of FET-PET led to an increase in GTV by 22-286% in eight patients and to a decrease of 23% and 26%, respectively, in two patients. In one patient, the final GTV was defined on the basis of MRI data only. CONCLUSIONS: FET-PET adds important information on the actual tumour volume in recurrent glioblastomas and is highly valuable for defining the target volume for the nano cancer therapy.
Authors: Jiangbing Zhou; Kofi-Buaku Atsina; Benjamin T Himes; Garth W Strohbehn; W Mark Saltzman Journal: Cancer J Date: 2012 Jan-Feb Impact factor: 3.360
Authors: Nathalie L Jansen; Vera Graute; Lena Armbruster; Bogdana Suchorska; Juergen Lutz; Sabina Eigenbrod; Paul Cumming; Peter Bartenstein; Jörg-Christian Tonn; Friedrich Wilhelm Kreth; Christian la Fougère Journal: Eur J Nucl Med Mol Imaging Date: 2012-04-11 Impact factor: 9.236
Authors: Sonu Bhaskar; Furong Tian; Tobias Stoeger; Wolfgang Kreyling; Jesús M de la Fuente; Valeria Grazú; Paul Borm; Giovani Estrada; Vasilis Ntziachristos; Daniel Razansky Journal: Part Fibre Toxicol Date: 2010-03-03 Impact factor: 9.400
Authors: Julia Y Ljubimova; Tao Sun; Leila Mashouf; Alexander V Ljubimov; Liron L Israel; Vladimir A Ljubimov; Vida Falahatian; Eggehard Holler Journal: Adv Drug Deliv Rev Date: 2017-06-10 Impact factor: 15.470
Authors: Daniele Barbaro; Lorenzo Di Bari; Valentina Gandin; Claudio Evangelisti; Giovanni Vitulli; Eleonora Schiavi; Cristina Marzano; Anna M Ferretti; Piero Salvadori Journal: PLoS One Date: 2015-04-15 Impact factor: 3.240
Authors: Adam J Grippin; Kyle A Dyson; Sadeem Qdaisat; James McGuiness; Brandon Wummer; Duane A Mitchell; Hector R Mendez-Gomez; Elias J Sayour Journal: J Neurooncol Date: 2020-08-05 Impact factor: 4.130